The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study.
Aged
Benzhydryl Compounds
/ administration & dosage
Blood Glucose
/ analysis
Blood Pressure
Body Weight
Cardiovascular Diseases
/ complications
Databases, Factual
Diabetes Complications
/ drug therapy
Diabetes Mellitus, Type 2
/ complications
Female
Glomerular Filtration Rate
Glucosides
/ administration & dosage
Humans
Male
Middle Aged
Patient Safety
Proportional Hazards Models
Risk Factors
Scotland
/ epidemiology
Sodium-Glucose Transporter 2 Inhibitors
/ administration & dosage
Systole
Treatment Outcome
Dapagliflozin
Glycaemic control
Type 2 diabetes
Journal
Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
21
05
2018
accepted:
30
11
2018
pubmed:
12
1
2019
medline:
19
2
2020
entrez:
12
1
2019
Statut:
ppublish
Résumé
Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is indicated for improving glycaemic control in type 2 diabetes mellitus. Whether its effects on HbA We used data from the comprehensive national diabetes register, the Scottish Care Information-Diabetes (SCI-Diabetes) collaboration database, available from 2004 to mid-2016. Data within this database were linked to mortality data from the General Registrar, available from the Information Services Division (ISD) of the National Health Service in Scotland. We calculated crude within-person differences between pre- and post-drug-initiation values of HbA Among 8566 people exposed to dapagliflozin over a median of 210 days the crude within-person change in HbA Dapagliflozin exposure was associated with reductions in HbA
Identifiants
pubmed: 30631892
doi: 10.1007/s00125-018-4806-9
pii: 10.1007/s00125-018-4806-9
doi:
Substances chimiques
Benzhydryl Compounds
0
Blood Glucose
0
Glucosides
0
Sodium-Glucose Transporter 2 Inhibitors
0
dapagliflozin
1ULL0QJ8UC
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
621-632Références
Lancet. 2005 Jan 1-7;365(9453):82-93
pubmed: 15639683
Diabetes Care. 2010 Oct;33(10):2217-24
pubmed: 20566676
Diabetes Care. 2014;37(3):740-50
pubmed: 24144654
Lancet Diabetes Endocrinol. 2016 Mar;4(3):211-220
pubmed: 26620248
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Diabetes Obes Metab. 2017 Aug;19(8):1106-1115
pubmed: 28240446
Diabetes Care. 2009 Apr;32(4):650-7
pubmed: 19114612
BMJ Open. 2014 Apr 07;4(4):e004619
pubmed: 24710132
Lancet Diabetes Endocrinol. 2017 Sep;5(9):680-681
pubmed: 28733172
Diabetes Care. 2015 Mar;38(3):365-72
pubmed: 25592197
Diabetes Obes Metab. 2014 Feb;16(2):159-69
pubmed: 23906445
J Clin Endocrinol Metab. 2012 Mar;97(3):1020-31
pubmed: 22238392
Ann Intern Med. 2012 Mar 20;156(6):405-15
pubmed: 22431673
Lancet Diabetes Endocrinol. 2016 Dec;4(12):1004-1016
pubmed: 27651331
Diabet Med. 2011 Dec;28(12):1514-9
pubmed: 21883441
J Diabetes Complications. 2013 Sep-Oct;27(5):473-8
pubmed: 23849632
Diabetes Obes Metab. 2014 Nov;16(11):1111-20
pubmed: 24919526
Diabetes Care. 2015 Nov;38(11):2009-17
pubmed: 26246458
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Biometrics. 1982 Dec;38(4):963-74
pubmed: 7168798
Diabetes Care. 2015 Sep;38(9):1638-42
pubmed: 26294774
Pharmacoepidemiol Drug Saf. 2017 Dec;26(12):1527-1533
pubmed: 29024286
Diabetes Obes Metab. 2018 May;20(5):1102-1110
pubmed: 29322605
Prim Care Diabetes. 2017 Oct;11(5):437-444
pubmed: 28583425
Diabetes Metab Res Rev. 2014 Mar;30(3):204-21
pubmed: 24115369
Diabetes Care. 2009 Sep;32(9):1656-62
pubmed: 19528367
Diabetes Care. 2012 Jul;35(7):1473-8
pubmed: 22446170
Lancet. 2010 Jun 26;375(9733):2223-33
pubmed: 20609968
Diabetologia. 2016 Oct;59(10):2106-13
pubmed: 27465219
N Engl J Med. 2016 Dec 8;375(23):2293-2297
pubmed: 27959688